-
公开(公告)号:US20050209240A1
公开(公告)日:2005-09-22
申请号:US10517438
申请日:2003-05-16
Applicant: Hans-Michael Eggenweiler , Norbert Beier , Pierre Schelling , Michael Wolf
Inventor: Hans-Michael Eggenweiler , Norbert Beier , Pierre Schelling , Michael Wolf
IPC: A61K31/50 , A61K31/501 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/04 , A61P7/06 , A61P9/10 , A61P11/00 , A61P11/06 , A61P11/08 , A61P13/02 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/06 , A61P19/10 , A61P21/00 , A61P21/04 , A61P25/00 , A61P25/14 , A61P25/16 , A61P25/24 , A61P25/28 , A61P25/30 , A61P27/02 , A61P27/16 , A61P29/00 , A61P31/04 , A61P31/10 , A61P31/16 , A61P31/18 , A61P31/22 , A61P33/06 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D237/04 , C07D401/12 , C07D403/12 , A61K31/53 , C07D43/02
CPC classification number: C07D401/12 , C07D237/04 , C07D403/12
Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
Abstract translation: 式(I)的芳基肟衍生物,其中R 1,R 2,R 3,X和B如权利要求中所定义, 1,作为磷酸二酯酶IV抑制剂,可用于治疗骨质疏松症,肿瘤,恶病质,动脉粥样硬化,类风湿性关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫性疾病,心肌疾病和艾滋病。
-
公开(公告)号:US06787548B1
公开(公告)日:2004-09-07
申请号:US10018484
申请日:2002-05-10
Applicant: Rochus Jonas , Pierre Schelling , Franz-Werner Kluxen , Maria Christadler
Inventor: Rochus Jonas , Pierre Schelling , Franz-Werner Kluxen , Maria Christadler
IPC: A61K31505
CPC classification number: C07D495/04
Abstract: Thienopyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2 and X have the meanings indicated in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of disorders of the cardiovascular system and for the treatment and/or therapy of potency disorders.
Abstract translation: 式I的噻吩并嘧啶及其生理上可接受的盐,其中R 1,R 2和X具有权利要求1所示的含义,表现出磷酸二酯酶V抑制,并且可用于治疗心血管系统疾病, 治疗和/或治疗效力障碍。
-
公开(公告)号:US6037349A
公开(公告)日:2000-03-14
申请号:US224355
申请日:1999-01-04
Applicant: Werner Mederski , Johannes Sombroek , Pierre Schelling , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck
Inventor: Werner Mederski , Johannes Sombroek , Pierre Schelling , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck
IPC: C07D471/04 , C07D471/02 , A61K31/415 , A61K31/44
CPC classification number: C07D471/04
Abstract: Imidazopyridine derivatives ad pharmacologically acceptable salts having antagonistic properties towards angiotensin II can be used for the treatment of hypertension, aldosteronism and cardiac insufficiency.
Abstract translation: 具有拮抗血管紧张素II拮抗作用的药理学上可接受的盐的咪唑并吡啶衍生物可用于治疗高血压,醛固酮增多和心功能不全。
-
公开(公告)号:US5405964A
公开(公告)日:1995-04-11
申请号:US139668
申请日:1993-10-22
Applicant: Werner Mederski , Dieter Dorsch , Andreas Bathe , Thorsten Hartig , Mathias Osswald , Norbert Beier , Pierre Schelling , Klaus-Otto Minck , Ingeborg Lues
Inventor: Werner Mederski , Dieter Dorsch , Andreas Bathe , Thorsten Hartig , Mathias Osswald , Norbert Beier , Pierre Schelling , Klaus-Otto Minck , Ingeborg Lues
IPC: A61K31/435 , A61K31/44 , A61P9/00 , A61P35/00 , A61P43/00 , C07D207/30 , C07D231/10 , C07D233/54 , C07D275/00 , C07D277/20 , C07D307/34 , C07D471/04 , C07D471/02 , C07D471/06
CPC classification number: C07D471/04
Abstract: Novel imidazopyridine derivatives of formula I ##STR1## and X, --Y.dbd.Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 as defined herein, and their salts, exhibit antagonistic properties towards angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
Abstract translation: 式I的新颖的咪唑并吡啶衍生物其中R为本文所定义的X为-Y = Z-,R1,R2,R3,R4和R5及其盐,对血管紧张素II表现出拮抗作用, 用于治疗高血压,醛固酮增多症,心功能不全和眼内压升高以及中枢神经系统疾病。
-
公开(公告)号:US5401738A
公开(公告)日:1995-03-28
申请号:US75247
申请日:1993-06-11
Applicant: Werner Mederski , Dieter Dorsch , Norbert Beier , Pierre Schelling , Ingeborg Lues , Klaus-Otto Minck , Mathias Osswald
Inventor: Werner Mederski , Dieter Dorsch , Norbert Beier , Pierre Schelling , Ingeborg Lues , Klaus-Otto Minck , Mathias Osswald
IPC: A61K31/50 , A61K31/54 , A61P9/12 , A61P25/00 , A61P43/00 , C07D257/04 , C07D257/06 , C07D403/04 , C07D403/14 , C07D405/14 , C07D409/14 , C07D413/14 , C07D417/04 , C07D417/14 , C07D471/04 , C07D471/14 , C07D521/00
CPC classification number: C07D403/04 , C07D403/14 , C07D417/04 , C07D417/14
Abstract: Benzimidazole compounds of the formula I ##STR1## and salts thereof, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and an increased intraocular pressure, as well as disturbances of the central nervous system.
Abstract translation: 式I的苯并咪唑化合物及其盐对血管紧张素II表现出拮抗作用,可用于治疗高血压,醛固酮增多症,心功能不全,眼内压升高以及中枢神经系统紊乱。
-
公开(公告)号:US5371226A
公开(公告)日:1994-12-06
申请号:US31977
申请日:1993-03-16
Applicant: Werner Mederski , Dieter Dorsch , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck , Pierre Schelling
Inventor: Werner Mederski , Dieter Dorsch , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck , Pierre Schelling
IPC: A61K31/47 , A61P9/00 , A61P9/12 , A61P43/00 , C07D215/22 , C07D215/227 , C07D215/54 , C07D401/06 , C07D401/10 , C07D401/14 , C07D413/06 , C07D413/14 , C07D215/48 , C07D215/50
CPC classification number: C07D215/227 , C07D401/10
Abstract: 2-oxoquinoline derivative of formula I; ##STR1## wherein R is ##STR2## and R.sup.1 to R.sup.6 and X are as defined in claim 1, and their salts exhibit antagonistic properties towards angiotensin II and have inter alia a hypotensive action.
Abstract translation: 式I的2-氧代喹啉衍生物; 其中R为
且R 1至R 6和X如权利要求1中所定义,并且它们的盐对血管紧张素II表现出拮抗作用,尤其是具有降血压作用。 -
公开(公告)号:US07544684B2
公开(公告)日:2009-06-09
申请号:US11497235
申请日:2006-08-02
Applicant: Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Pierre Schelling , Thomas Ehring
Inventor: Hans-Michael Eggenweiler , Michael Wolf , Norbert Beier , Pierre Schelling , Thomas Ehring
IPC: A61K31/50 , A61K31/501 , A61P11/06
CPC classification number: C07D403/12 , C07D237/04
Abstract: Hydrazono-malonitrile derivatives of the formula (I) in which R1, R2, R3, R3′ and R4 have the meanings given in Claim 1 act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumors, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
Abstract translation: 其中R 1,R 2,R 3,R 3'和R 4具有权利要求1中给出的含义的式(I)的肼基 - 丙腈衍生物作为磷酸二酯酶IV抑制剂起作用,可用于治疗骨质疏松症,恶病质,恶病质,动脉粥样硬化, 类风湿关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫性疾病,心肌疾病和艾滋病。
-
公开(公告)号:US07470687B2
公开(公告)日:2008-12-30
申请号:US11429181
申请日:2006-05-08
Applicant: Hans-Michael Eggenweiler , Norbert Beier , Pierre Schelling , Michael Wolf
Inventor: Hans-Michael Eggenweiler , Norbert Beier , Pierre Schelling , Michael Wolf
IPC: A61K31/501 , A61K31/50
CPC classification number: C07D401/12 , C07D237/04 , C07D403/12
Abstract: Aryl oxime derivatives of the formula (I), in which R1, R2, R3, X and B are as defined in Claim 1, act as phosphodiesterase IV inhibitors and can be employed for the treatment of osteoporosis, tumours, cachexia, atherosclerosis, rheumatoid arthritis, multiple sclerosis, diabetes mellitus, inflammatory processes, allergies, asthma, autoimmune diseases, myocardial diseases and AIDS.
Abstract translation: 式(I)的芳基肟衍生物,其中R 1,R 2,R 3,X和B如权利要求1所定义,作为磷酸二酯酶IV抑制剂,可用于治疗骨质疏松症,肿瘤,恶病质,动脉粥样硬化,类风湿 关节炎,多发性硬化,糖尿病,炎症过程,过敏,哮喘,自身免疫疾病,心肌疾病和艾滋病。
-
公开(公告)号:US07259168B2
公开(公告)日:2007-08-21
申请号:US10312767
申请日:2001-06-28
Applicant: Rochus Jonas , Pierre Schelling , Maria Christadler , Norbert Beier
Inventor: Rochus Jonas , Pierre Schelling , Maria Christadler , Norbert Beier
IPC: A01N43/90
CPC classification number: C07D495/04
Abstract: The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) in which the radicals R1 to R6 have the meaning indicated in the text. The compounds show phosphodiesterase V inhibition and can be employed for the treatment of conditions of the cardiovascular system and for the treatment of potency disorders.
Abstract translation: 本发明涉及通式(I)的2-氨基甲基噻吩并[2,3-d]嘧啶,其中R 1至R 6基团具有所述含义 在文中。 化合物显示磷酸二酯酶V抑制,并且可用于治疗心血管系统的病症和治疗效力障碍。
-
公开(公告)号:US5798364A
公开(公告)日:1998-08-25
申请号:US725242
申请日:1996-10-04
Applicant: Werner Mederski , Johannes Sombroek , Pierre Schelling , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck
Inventor: Werner Mederski , Johannes Sombroek , Pierre Schelling , Norbert Beier , Ingeborg Lues , Klaus-Otto Minck
IPC: C07D471/04 , A61K31/415 , C07D471/06
CPC classification number: C07D471/04
Abstract: Imidazopyridine derivatives and pharmacologically acceptable salts having antagonistic properties towards angiotensin II can be used for the treatment of hypertension, aldosteronism and cardiac insufficiency.
Abstract translation: 对血管紧张素II有拮抗作用的咪唑并吡啶衍生物和药理学上可接受的盐可用于治疗高血压,醛固酮增多和心功能不全。
-
-
-
-
-
-
-
-
-